RxDoctor Payments Data

Michelle Powell, MD

Family Medicine · Miami, FLNPI 1154350577

Payments from drug & device makers

$34,130in general payments, 2019–2025

Across 229 payments — averaging $149.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$22K
  • Gilead$10K
  • Merck$459
  • Johnson & Johnson$441
  • Janssen Products, LP$129
  • Pfizer$95
  • plus $278 from 9 others

What the payments were for

  • Consulting fees$19,82358%
  • Speaking & faculty fees$8,50425%
  • Travel & lodging$1,2624%
  • Food & beverage$4,41313%
  • Education$1290%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,130 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$39,619
Medicare patients
65
Services billed
412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala477$1,917,477
DovatoDolutegravir Sodium/Lamivudine211$611,834
TivicayDolutegravir Sodium232$610,478
DescovyEmtricitabine/Tenofov Alafenam240$527,599
OdefseyEmtricitab/Rilpiviri/Tenof Ala110$396,362
PifeltroDoravirine160$274,249
JulucaDolutegravir/Rilpivirine53$188,641
TriumeqAbacavir/Dolutegravir/Lamivudi34$127,733
PrezcobixDarunavir/Cobicistat46$120,707
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf25$117,946
Maraviroc57$72,841
IsentressRaltegravir Potassium31$60,217
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df44$58,976
GenvoyaElviteg/Cob/Emtri/Tenof Alafen13$52,385
IntelenceEtravirine37$51,541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$10,393$2,497,462730 claims
Viiv Healthcare CompanyDovato, Tivicay, Juluca, Triumeq$22,335$1,538,687530 claims
MerckPifeltro, Isentress$459$334,466191 claims
Johnson & JohnsonPrezcobix$441$120,70746 claims
Janssen Products, LPSymtuza$129$117,94625 claims
Lilly USA, LLCTrulicity, Mounjaro$27$42,34141 claims
PfizerEliquis, Premarin$95$22,60239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →